Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis jamanetwork.com/journals/jam… Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial. Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer @NicholasZaorsky @yilun_sun @StatMatt9 @DrHowardSandler @drjefstathiou @Soum_Roy_RadOnc @DrPaulNguyen @jeshoag @PBarataMD @angela_jia_ @MSteinbergMD @AmarUKishan @DrSpratticus @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

ENZARAD (ANZUP 1303) Presented at #ESMO25 ADT with radiation therapy with or without enzalutamide for high risk, clinically localised #ProstateCancer cslide.ctimeetingtech.com/es… Adding enzalutamide to ADT 💊and radiation provided limited overall survival benefit in high-risk localized or locally advanced prostate cancer, with greater metastasis-free survival seen in patients with positive pelvic nodes or planned pelvic radiation☢️ @DrPaulNguyen @ChrisSweens1 @MartinStockler @DocJarad @DavePryorRO @PaulKRadiation @Prof_IanD @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima